c An enzyme immunoassay kit that detects serum IgA antibody reacting to glycopeptidolipid core antigen derived from Mycobacterium avium complex (MAC) was not useful for differentiating MAC pulmonary disease (PD) from Mycobacterium abscessus complex PD (MAB-PD). However, this assay could be useful for differentiating MAC-and MAB-PD from pulmonary tuberculosis. (This study has been registered at ClinicalTrials.gov under registration no. NCT00970801.) A n enzyme immunoassay (EIA) that detects serum immunoglobulin A (IgA) antibody reacting to the glycopeptidolipid (GPL) core antigen of Mycobacterium avium complex (MAC) was developed (1). This EIA kit was useful for rapid diagnosis of MAC pulmonary disease (MAC-PD) and for differentiating MAC-PD from pulmonary tuberculosis (PTB) (1-5).
the best cutoff point, which showed the highest Youden index ([sensitivity ϩ specificity] Ϫ 1) (12) . The discriminative power of the EIA kit was assessed by calculating the area under the receiver operating characteristic curve (AUC). We used STATA ver. 11 (STATA Corp., College Station, TX) for all analyses and considered a 2-sided P of Ͻ0.05 to be statistically significant.
The median age was 62 (IQR, 49 to 70) years in the MAC-PD patient group, 56 (IQR, 48 to 68) years in the MAB-PD patient group, 60 (IQR, 53 to 67) years in the PTB patient group, and 56 (IQR, 52 to 61) years in the control groups. The proportions of male patients were 40%, 23%, 75%, and 50% in the MAC-PD, MAB-PD, PTB, and control groups, respectively. The proportions of patients with the nodular bronchiectatic form of MAC-and MAB-PD were 83% and 80%, respectively. None of the subjects were positive for human immunodeficiency virus infection. Figure 1A shows a scattergram of IgA antibody titers plotted against the GPL core antigen in each group. Significantly higher levels were detected in the MAC-PD group (median, 6.96; IQR, 1.12 to 14.00 U/ml) than in the other groups (P ϭ 0.030 for MAB-PD, P Ͻ 0.001 for PTB, and P Ͻ 0.001 for the control group). However, the MAB-PD group (median, 1.28; IQR, 0.54 to 4.43 U/ml) also had a higher titer than the PTB group (median, 0.09; IQR, 0.07 to 0.11 U/ml; P Ͻ 0.001) and controls (median, 0.08; IQR, 0.07 to 0.10 U/ml; P Ͻ 0.001). The positivity rates for the EIA were 85%, 70%, 0%, and 0% in the MAC-PD, MAB-PD, PTB, and control groups, respectively.
In the study subjects, excluding MAB-PD, the discriminatory power for detection of MAC-PD was high (AUC, 0.98; 95% confidence interval [CI], 0.95 to 1.00), with 85% sensitivity, 100% specificity, and 100% PPV at a preset cutoff of 0.7 U/ml, which were similar to values seen at the best cutoff point (Ն0.69 U/ml) (Fig. 1B) . Among all study subjects, including those with MAB-PD, however, the discriminatory power and the PPV for detection of MAC-PD were weakened to an AUC of 0.83 (95% CI, 0.76 to 0.90), with 85% sensitivity, 65% specificity, and 54.8% PPV at a preset cutoff value and 72.5% sensitivity, 82.5% specificity, and 67.4% PPV at the best cutoff point (Ն1.70 U/ml) (Fig. 1C) . In terms of distinguishing NTM lung disease (both MAC-and MAB-PD) from others (PTB and control groups), the AUC was 0.96 (95% CI, 0.92 to 0.99), with 77.5% sensitivity, 100% specificity, and 100% PPV at a preset cutoff value and 85% sensitivity, 100% specificity, and 100% PPV at the best cutoff point (Ն0.52 U/ml) (Fig. 1D ).
NTM causes a chronic, slowly progressive pulmonary infection that resembles PTB. In clinical practice, it is difficult to distinguish NTM-PD from PTB, because the symptoms and radiographic findings are often similar. This leads to an incorrect diagnosis or unnecessary treatment in many patients with NTM-PD (13) . Therefore, serodiagnosis of NTM-PD could be useful for rapid differentiation of NTM-PD from PTB. Our data revealed that this EIA kit could be useful for differential serodiagnosis of MAC-PD and PTB, which is consistent with previous studies (1-5).
We found that the level of serum IgA antibody to the GPL core antigen was higher in both MAB-and MAC-PD patients. In fact, (14, 15) . A previous study from Japan reported that this EIA kit could discriminate MAC-PD from M. kansasii PD (1). Because GPL is not located on the surface of the M. kansasii cell wall (16) , this finding seems reasonable. Therefore, this EIA kit is not useful for prediction of NTM etiology, especially in countries in which MAB is a relatively common etiology of NTM lung disease.
Antibody titers in our patients with MAC-PD were higher than those in Caucasian patients (4) and similar to those in Japanese patients (3, 5) . Differences in race, disease status, and etiological proportion may affect these results and the best cutoff value. Finally, because of high PPV and low NPV (Fig. 1D) , a high value of serum IgA antibody could be in favor of NTM infection but a low value could not exclude a possibility of NTM infection.
In summary, this EIA kit that detects serum IgA antibody to the GPL core antigen cannot differentiate MAC-PD from MAB-PD. Therefore, caution in the interpretation of the test results should be required in countries such as the United States and South Korea in which MAB is a common etiology of NTM lung disease. In addition, this kit could be useful for differentiating NTM-PD, including MAC-and MAB-PD, from PTB instead of for differentiating MAC-PD from MAB-PD. We declare that we have no conflicts of interest.
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